Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes

We present a cohort of primarily non-Asian patients with advanced stage and relapsed/refractory ENKL. Our results demonstrate that achievement of complete response (CR) is imperative at all stages of disease in order to attain long-term disease control. The SMILE regimen was effective in relapsed/refractory disease to achieve complete remission. Autologous stem cell transplant should be strongly considered in patients with advanced ENKL who achieved CR, whereas allo-SCT can be considered for select patients who have not attained a CR.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

AbstractIt is well established that some rheumatic syndromes (RS) are associated with several hematological malignancies. We aimed to describe the clinical course of patients with hematological malignancies mimicking RS. We studied a series of four patients presenting with apparent RS who were eventually diagnosed with hematological malignancies, and reviewed the relevant literature. Our series consisted of 4 patients, with a mean age of 62.8  ± 20.3 years, who presented to our rheumatology unit between December 2012 and March 2018. Two patients were initially diagnosed with polyarthritis. One of these...
Source: Rheumatology International - Category: Rheumatology Source Type: research
Publication date: Available online 1 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Benjamin Heyman, Anne Beaven
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
In this report we present a patient with subcutaneous panniculitis-like T-cell lymphoma, who has been successfully treated with mycophenolate mofetil.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
ConclusionOur study has shown that 90% of PTCL cases will be FDG avid. However, PET/CT was not predictive for PFS or OS at any point. The only predictive factor was the presence of lymphopenia.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 27 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Ryo Ichinohasama, Hideo HarigaeAbstractA 53-year-old male suffering from fever, multiple skin nodules and gastric ulcer had been diagnosed as a rare and aggressive subtype of malignant lymphoma with a γδ T-cell phenotype. Cord blood transplantation was performed after achievement of a certain disease control by some courses of chemotherapy. Unfortunately lymphoma relapsed as early as two months after transplantation; however, it has been successfully and cont...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: July 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 7Author(s): Anuhya Kommalapati, Sri Harsha Tella, Apar Kishore Ganti, James O. ArmitageAbstractBackgroundLimited data are available regarding the incidence, survival patterns, and long-term outcomes of natural killer (NK)/T-cell neoplasms in the United States.Patients and MethodsWe performed a retrospective study of patients with NK/T-cell neoplasms diagnosed from 2001 to 2014 using the Surveillance, Epidemiology, and End Results program database. The Kaplan-Meier method was used to estimate the overall survival difference among the...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionIn this series of adults with HLH, patients with nosocomial infections and neurological symptoms had a statistically significant worse OS. It is the largest series in Latin America, the most common cause of HLH was T-cell lymphoma. In our population, NM-HLH presented a higher mortality.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 27 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Francine M. Foss, Terri L. Parker, Michael Girardi, Anlong LiSummaryCutaneous T-cell lymphomas (CTCL) are rare, heterogeneous non-Hodgkin lymphomas with poor prognoses. Treatment options for CTCL are limited by the their efficacy and tolerability profile. Pralatrexate has demonstrated efficacy in T-cell lymphomas, however dose-modifying adverse events, such as mucositis have occurred. We retrospectively reviewed clinical responses and toxicity in 27 CTCL patients treated with pralatrexate at doses ranging from 10-30mg/...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsOur study shows that 90% of PTCL are FDG avid. Yet, PET/CT was not predictive for PFS or OS at any time point. The only predictive factor was lymphopenia.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 27 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Ryo Ichinohasama, Hideo HarigaeAbstractA 53-year-old male suffering from fever, multiple skin nodules and gastric ulcer had been diagnosed as a rare and aggressive subtype of malignant lymphoma with a γδ T-cell phenotype. Cord blood transplantation was performed after achievement of a certain disease control by some courses of chemotherapy. Unfortunately lymphoma relapsed as early as two months after transplantation; however, it has been successfully and cont...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Study | T-cell Lymphoma | Transplants